Ursodeoxycholic Acid Market Size, Key players Analysis 2031Posted by pooja on August 3rd, 2022  Ursodeoxycholic acid (UDCA) is essentially bile acid ingested in the liquid form or in the form of a tablet to cure gallstones. Those can cure or thwart the progress of cystic fibrosis-related liver disorder. UDCA transforms the bile acid pool by lowering the levels of hydrophobic bile acids. This increases the amount of nontoxic hydrophilic bile acids. Besides, UDCA can slow down the development of gastroesophageal varices and progression to cirrhosis. Further, it can also better chances of survival of patients. Cholestatic liver diseases are at the forefront of driving demand in the global ursodeoxycholic acid market. Rising instances of gall stones and cystic fibrosis is in large part responsible for driving the market. As per 2015 data released by Cystic Fibrosis Foundation, about 30,000 people are afflicted with cystic fibrosis in the U.S. alone. Women are highly prone to having gallstones when compared to men. This is mainly because of the high levels of estrogen during pregnancy, hormone replacement therapy, and usage of birth control pills. Further, older adults are also highly susceptible to gallstones along with those having a family history of gallstones. While surgery is the most widespread treatment for it, ursodeoxycholic acid can dissolve smaller stones formed mostly of cholesterol. This is having a positive impact on the market. Some of the prominent participants in the global ursodeoxycholic acid market are Arcelor Chemicals, Abil Chempharma, Daewoong Chemical, Biotavia Labs, and Dipharma Francis. Market competition is intense. The overall ursodeoxycholic acid market is highly competitive and with consumer awareness will grow in future. Request Sample Copy @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=4218 About TMR Research Like it? Share it! More by this author |